Pfizer to Buy Rest of Biohaven for $11.6 Billion
Pfizer Inc.
PFE 2.13%
agreed to buy the rest of
Biohaven Pharmaceutical Holding Co.
BHVN 70.70%
for about $11.6 billion, deploying its pile of cash earned from Covid-19 sales to acquire a new migraine drug.
Pfizer said it would pay $148.50 a share in cash for the Biohaven shares that it doesn’t already own, a nearly 79% premium to Monday’s closing price of $83.14 for the New Haven,…